Article Details

Bio-Thera initiates Phase I solid tumour antibody combo trial in Australia

Retrieved on: 2022-03-31 14:48:16

Tags for this article:

Click the tags to see associated articles and topics

Bio-Thera initiates Phase I solid tumour antibody combo trial in Australia. View article details on hiswai:

Excerpt

A highly differentiated monoclonal antibody, BAT6026 acts on OX40 with improved antibody-dependent cellular cytotoxicity (ADCC) functions.

Article found on: www.clinicaltrialsarena.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up